Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report
| dc.contributor.author | Waterhouse, Deirdre F | |
| dc.contributor.author | Moloney, Geraldine A | |
| dc.contributor.author | Gargoum, Fatma S | |
| dc.contributor.author | Hayden, Peter S | |
| dc.contributor.author | O'Gorman, Tom | |
| dc.date.accessioned | 2016-09-30T11:16:40Z | |
| dc.date.available | 2016-09-30T11:16:40Z | |
| dc.date.issued | 2009-09-14 | |
| dc.identifier.citation | Cases Journal. 2009 Sep 14;2(1):7456 | en |
| dc.identifier.uri | http://dx.doi.org/10.4076/1757-1626-2-7456 | |
| dc.identifier.uri | http://hdl.handle.net/10147/620770 | |
| dc.description.abstract | Abstract Intracranial plasmacytomas are an uncommon presentation of extramedullary relapse of multiple myeloma. The optimal management of extramedullary plasmacytomas remains unclear, with initial reports of bortezomib showing promising clinical results. We describe a case of multiple extracellular, including intracranial, plasmacytoma, with no evidence of marrow involvement, in a patient with relapsed IgA multiple myeloma. To our knowledge, this is the first reported case of a patient with rapid extramedullary relapse of disease despite recent exposure to bortezomib and dexamethasone. | |
| dc.language.iso | en | en |
| dc.subject.other | MYELOMA | en |
| dc.title | Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report | en |
| dc.language.rfc3066 | en | en |
| dc.rights.holder | licensee BioMed Central Ltd. | en |
| dc.date.updated | 2016-04-15T16:03:59Z | en |
| refterms.dateFOA | 2018-08-27T16:56:50Z | |
| html.description.abstract | Abstract Intracranial plasmacytomas are an uncommon presentation of extramedullary relapse of multiple myeloma. The optimal management of extramedullary plasmacytomas remains unclear, with initial reports of bortezomib showing promising clinical results. We describe a case of multiple extracellular, including intracranial, plasmacytoma, with no evidence of marrow involvement, in a patient with relapsed IgA multiple myeloma. To our knowledge, this is the first reported case of a patient with rapid extramedullary relapse of disease despite recent exposure to bortezomib and dexamethasone. |
